MTEM Molecular Templates

Molecular Templates to Participate in Upcoming Virtual Investor Conferences

Molecular Templates to Participate in Upcoming Virtual Investor Conferences

AUSTIN, Texas, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, today announced that it will present and participate in 1-on-1 investor meetings at the Cowen 41st Annual Health Care Conference, the Barclays Global Healthcare Conference and the Oppenheimer 31st Annual Healthcare Conference.

Cowen 41st Annual Health Care Conference

Conference Dates: March 1-4

Presentation Date and Time: Thursday, March 4th at 11:10 AM ET

        

Barclays Global Healthcare Conference

Conference Dates: March 9-11

Presentation Date and Time: Wednesday, March 10th at 3:00 PM ET

Oppenheimer 31st Annual Healthcare Conference

Conference Dates: March 16-17

Presentation Date and Time: Wednesday, March 17th at 11:20 AM ET         

Live webcasts of these presentations will be available in the “News and Events” section of the MTEM website at . Additionally, replays of the webcasts will be available on the corporate website following the conferences. 

About Molecular Templates  

Molecular Templates is a clinical-stage company focused on the discovery and development of targeted biologic therapeutics. Our proprietary drug platform technology, known as engineered toxin bodies, or ETBs, leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer and other serious diseases.

Investor Contact:

Adam Cutler

Chief Financial Officer



862-204-4006

Source: Molecular Templates, Inc.



EN
26/02/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Molecular Templates

 PRESS RELEASE

Molecular Templates Announces Notice of Delisting and Failure to Satis...

Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules AUSTIN, Texas, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, was notified on December 16, 2024 by the Listing Qualifications Department (the “Staff”) of The Nasda...

 PRESS RELEASE

Molecular Templates Announces Receipt of Expected Notification of Defi...

Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price Requirements AUSTIN, Texas, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, announc...

 PRESS RELEASE

Molecular Templates, Inc. Reports Second Quarter 2024 Financial Result...

Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update Monotherapy activity of long duration in patients who have progressed on checkpoint therapy via a novel immuno-oncology mechanism of action with PD-L1 ETB (MT-6402) programEarly indication of monotherapy activity in CTLA-4 ETB (MT-8421) program through T-reg depletion; no drug-related adverse events > grade 2Novel mechanism of action targeting CD38+ immune cells of B-cell, T-cell, and monocytic lineage representing enhanced potency in I&I without the need for conditioning therapy AUSTIN, Texas, Aug...

 PRESS RELEASE

Molecular Templates, Inc. Provides Interim Update

Molecular Templates, Inc. Provides Interim Update Continued monotherapy activity in solid tumors with MT-6402 (PD-L1-targeting ETB) in checkpoint-experienced patients.Early pre-clinical and clinical data demonstrate the potential of MT-0169 (CD38-targeting ETB) in severe immune-mediated diseases. AUSTIN, Texas, June 03, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage company focused on the discovery and development of targeted biologic therapeutics with unique mechanisms of action (engineered toxin bodies or “ETBs”) fo...

 PRESS RELEASE

Molecular Templates, Inc. Reports First Quarter 2024 Financial Result...

Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action, today reported financial results and business updates for the first quarter of 2024. Recent Company Highlights MTEM presented clinical d...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch